| Recruitment status | Main results already published |
| Unique ID issued by UMIN | UMIN000014533 |
| Receipt No. | R000016885 |
| Scientific Title | Study on effects of a plant-derived protein containing food product on postprandial hyperglycemia |
| Date of disclosure of the study information | 2014/07/15 |
| Last modified on | 2019/07/25 (Ver. 13) |
| Basic information | ||
| Public title | Study on effects of a plant-derived protein containing food product on postprandial hyperglycemia | |
| Acronym | Study on effects of a plant-derived protein containing food product on postprandial hyperglycemia | |
| Scientific Title | Study on effects of a plant-derived protein containing food product on postprandial hyperglycemia | |
| Scientific Title:Acronym | Study on effects of a plant-derived protein containing food product on postprandial hyperglycemia | |
| Region |
|
|
| Condition | ||
| Condition | Postprandial hyperglycemia | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To investigate effects of a food product on postprandial hyperglycemia |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | postprandial blood glucose |
| Key secondary outcomes | Insulin, TG, GIP, GLP-1, ghrelin, appetite (satiety) |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Cross-over |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | placebo food | |
| Interventions/Control_2 | active food | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male | |||
| Key inclusion criteria | 1, Fasting blood glucose > 94, and <126 mg/dL
2, HbA1c (NGSP) > 5.1, and <6.5 3, Aged between 30 and 59 4, BMI >22.9 and <30 kg/m2 5, Person who can accept to be accessed their medical records and agree with the study protocol followed by a prior explanation 6, Person who provides informed consent by a document 7, Depends on the screening condition of above 1 to 3 criteria, person who does not meet the criteria can be screened in case that the physican in charge, the client and the CRO reach to agreement of it. |
|||
| Key exclusion criteria | 1, Person who is difficult to participate the study due to dysfunctions of liver, kidney, heart, respiration, endocrine secretion, metabolism, nervous system, consciousness or diabetes, or the other dysfunctions
2, Person who was given surgery for a disease or an injury 2 months prior to the study 3, Person who was given gastrectomy and/or bypass of part of the intestine 4, Person who takes medication for glucose or fat metabolism, or hypertension 5, Person who habitually consumes the foods for specific health use (FOSHU) and/or dietary supplements (capsules) (except for person who can stop to consume them right after informed consent) 6, Person who is or had been given treatment for allergies to test food ingredients 7, Person who has been ill due to blood collecting 8, Person who donated 200mL or more of blood within a month prior to the study 9, Person who skip breakfast habitually 10, Heavy smoker or person who cannot stop |
|||
| Target sample size | 20 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Kao Corporation | ||||||
| Division name | Health Care Food Research Labs. | ||||||
| Zip code | 131-8501 | ||||||
| Address | 2-1-3 Bunka Sumida-ku Tokyo | ||||||
| TEL | 03-5630-7456 | ||||||
| saito.shinichiro@kao.co.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | TES Holdings Co. Ltd | ||||||
| Division name | Sales department for tissue engineering and clinical research | ||||||
| Zip code | 103-0027 | ||||||
| Address | Tokyo Univ 6F, 7-3-1, Hongo, Bunkyo-ku, Tokyo | ||||||
| TEL | 03-6801-8480 | ||||||
| Homepage URL | |||||||
| t.tamura@tes-h.co.jp | |||||||
| Sponsor | |
| Institute | Kao Corporation |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Kao Corporation |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | the Ethical Committee of the Oriental Ueno Kenshin Center |
| Address | 1-20-11 Ueno, Taito-ku, Tokyo |
| Tel | 03-5816-0711 |
| ueno-center@oriental-gr.com | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 医療法人 相生会 墨田病院 |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | Unpublished due to the protocol including the intellectual property rights |
| Publication of results | Published |
| Result | |||||||
| URL related to results and publications | https://www.mdpi.com/2072-6643/11/1/187 | ||||||
| Number of participants that the trial has enrolled | 20 | ||||||
| Results | There was a significantly difference in the primary outcome between the groups |
||||||
| Results date posted |
|
||||||
| Results Delayed | |||||||
| Results Delay Reason | |||||||
| Date of the first journal publication of results | |||||||
| Baseline Characteristics | healthy men |
||||||
| Participant flow | 22 were screened and 20 were analyzed |
||||||
| Adverse events | No adverse events occurred associated with consumption of the test diets |
||||||
| Outcome measures | Postprandial blood glucose |
||||||
| Plan to share IPD | |||||||
| IPD sharing Plan description | |||||||
| Progress | |||||||
| Recruitment status | Main results already published | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016885 |